# Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

> **NCT06430684** · EARLY_PHASE1 · RECRUITING · sponsor: **Ann & Robert H Lurie Children's Hospital of Chicago** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Kidney Diseases
- Pediatric Kidney Disease

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT06430684
- **Lead sponsor:** Ann & Robert H Lurie Children's Hospital of Chicago
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-23
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06430684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06430684, "Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06430684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*